The Patent Finder

Synbias Pharma AG

Also on record
Records under this name other than the patents Synbias Pharma AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Showing 1 to 6 of 6 · Back to Synbias Pharma AG

PatentTitleStatus Expires Confidence
US 10,526,290Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy
Lapsed on the fee record
Ended Jan 7, 2024 · From the USPTO record
Lapsed on the fee recordEnded Jan 7, 2024From the USPTO record
US 10,294,208Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy
Lapsed on the fee record
Ended May 21, 2023 · From the USPTO record
Lapsed on the fee recordEnded May 21, 2023From the USPTO record
US 8,846,882Method of producing 4-demethoxydaunorubicin
Lapsed on the fee record
Ended Sep 30, 2022 · From the USPTO record
Lapsed on the fee recordEnded Sep 30, 2022From the USPTO record
US 8,809,549Esters of bendamustine and related compounds, and medical use thereof
Lapsed on the fee record
Ended Aug 19, 2022 · From the USPTO record
Lapsed on the fee recordEnded Aug 19, 2022From the USPTO record
US 10,030,043Method for the synthesis of clofarabine
Lapsed on the fee record
Ended Jul 24, 2022 · From the USPTO record
Lapsed on the fee recordEnded Jul 24, 2022From the USPTO record
US 9,765,083Method for the synthesis of irinotecan
Lapsed on the fee record
Ended Sep 19, 2021 · From the USPTO record
Lapsed on the fee recordEnded Sep 19, 2021From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited